For capmatinib targeting MET in EGFR mutated lung adenocarcinoma with disease progression on EGFR-TKI treatment, gains of ≥ 6 copies have been related to response to combined MET and EGFR targeting [19]. Here, MET is linked to lung adenocarcinoma.